We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on «Accept All», you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on «Confirm». Find detailed information and modify your preferences at any time in our Privacy Notice.
Cookies necesarias Siempre activas
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
Cookies analíticas
We would like to set Google Analytics cookies to help us analyse the traffic on our website.
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
Arcera Life Sciences Convenes Global Healthcare Leaders in Abu Dhabi to Accelerate...
Held during the annual “UAE Innovates” month, which aims to reinforce the UAE’s position as an international beacon of innovation,...
Arcera Life Sciences Drives Healthcare Innovation with Strategic ISPOR UAE Chapter Partnership...
Signed during the ISPOR UAE Chapter 2026 Conference in Abu Dhabi, the Memorandum of Understanding (MoU) coincides with the launch...
Ariprazol® Receives Qualification Release in the EU and Launches Sales in Latvia
Acino, part of Arcera, has obtained a qualification release for its prescription antipsychotic medicine Ariprazol® (aripiprazole) in the European Union,...
Arcera Life Sciences releases inaugural Sustainability Report
The 2024 report outlines Arcera’s current ESG initiatives and long-term ambitions, including a firm commitment to achieving full carbon neutrality...
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug...
Seongnam-si, South Korea and Abu Dhabi, UAE – June 10, 2025 – AriBio Co., Ltd. («AriBio»), a South Korean biopharmaceutical company...
Achieving Level 1 B-BBEE status in South Africa for the sixth year...
For the sixth consecutive year, Acino has achieved Level 1 Broad-Based Black Economic Empowerment (B-BBEE) contributor status in South Africa.
Leadership Announcements and New Arcera Structure
Arcera aims to become a global life sciences company, with the purpose of enabling longer and healthier lives while driving...
Acino signs an exclusive agreement with LG Chem for Novel Treatments for...
Acino will market, commercialize, and distribute Hyruan One® in Brazil, and Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico) in...
ADQ launches holding company Arcera to build a global life sciences powerhouse...
Abu Dhabi, UAE – 01/04/2024: ADQ, an Abu Dhabi-based investment and holding company, has announced the formation of Arcera, a...
Acquisition of M8 Pharmaceuticals and integration into Acino
With nearly 300 new employees on board, Acino will enhance its presence in Latin America and strengthen its business through...